PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Format: Artigo
Langue:Inglês
Publié: Paediatrician Publishers, LLC 2012-08-01
Collection:Pediatričeskaâ Farmakologiâ
Sujets:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Accès en ligne:https://www.pedpharma.ru/jour/article/view/302
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires